Executive Management Team
Roger Hinton, Managing Director
Dr Roger Hinton has over 30 years’ experience within the pharmaceutical industry both at the operational and management level and has worked in research, product and process development and business development. Dr Hinton has a B. Sc. (Hons) in Microbiology and Ph.D. in microbial enzymology. He was formerly the PHE Head of Development and Production and is now the Managing Director of Porton Biopharma Limited.
Howard Tranter, Commercial Director
Dr Howard Tranter, has over 30 years’ experience working in the development and manufacture of biologics from commercially useful microbial pathogens. He was involved in the development of Dysport®, a therapeutic form of botulinum type A toxin and its successful licensure to Ipsen Ltd. Prior to joining Porton Biopharma he held a Senior Business Development Manager position with Public Health England with particular responsibilities for Development and Production activities and was responsible for initiating and maintaining public-private collaborations with commercial vaccine developers and manufacturers and the licensing of PHE technology to such partners.
Shane Jones, Director of Production
Shane has a B. Sc. (Hons) degree in Biochemistry and over 20 years’ experience in the biopharmaceutical industry. He has held management positions in both Quality Control and Manufacturing divisions and has significant experience of regulatory inspections. Shane joined HPA/PHE as Deputy Head of Manufacturing in 2009 becoming Head of Manufacturing in 2012. Prior to this, Shane spent 17 years at Therapeutic Antibodies UK Limited/Protherics UK Limited, comprising 9 years as Quality Control Manager and 7 years as Production Manager/Head of Manufacturing. In his role as Head of Manufacturing at Protherics, Shane also headed Technical Support and Process Development functions.
Trevor Marks, Director of Development
Trevor has a degree in Biochemistry and a PhD in Environmental Biochemistry. He has extensive experience working in the pharmaceutical industry in a number of roles including research, production, product and process development and project management. He has managed the Process & Analytical Development Group in PHE for over 5 years, and continues this role with Porton Biopharma Limited.
Peter Hughes, Director of Quality
Dr Peter Hughes has over 30 years’ experience within the biotechnology and pharmaceutical sectors at operational and management level and has held positions in R&D, process development, manufacturing and Quality. This includes periods with British Biotechnology plc. and the Institute of Biotechnology, University of Cambridge. Dr Hughes has a B. Sc. (Hons) degree in applied biology and Ph.D. in protein biochemistry.
Brian Pollard, Director of Engineering
After receiving his Master’s Degree, Brian has held a number of senior engineering positions in the API and Biopharmaceutical industry including Sigma Aldrich, and Foster Wheeler Energy. Brian is a Chartered Chemical Engineer with significant experience in the fields of pharmaceutical facility design, operation, quality systems, project management and delivery of major capital projects.
Alan Jennings, Director of Regulatory Affairs
After obtaining a B. Sc. degree in Microbiology and a Ph. D. in Molecular Biology, Alan worked in the US for a period before returning to the UK. He has considerable experience in the pharmaceutical industry, having held senior positions in project management, Quality Assurance and Quality Control. He has experience in Regulatory Affairs relating to the EU, US and Japan.
Roger Price, Director of Logistics & Project Management
Roger Price has over 30 years’ experience in the life science industry including the last 10 years within a pharmaceutical manufacturing based organisation. A graduate chemist he has previously held positions in QC, manufacturing, development and research with GE Life Sciences.
Nigel Mackie, Company Secretary
After obtaining a degree in Economics & Statistics, Nigel qualified as an accountant. He has extensive experience working in a variety of senior finance roles in the private sector, in both the service and manufacturing industries; this includes periods with LRV Industries, Warner Lambert (Pfizer) and Coopervision, both in the UK and overseas.
Amir Malik, Finance Director
Amir has 20 years experience in a range of strategic finance roles is a qualified chartered accountant, has an MBA in finance, a BSc in Chemistry and is a member of the Institute of Chartered Accountants in England and Wales (ICAEW). Prior to this appointment, he was a finance consultant for the Department of Health (DH), where his roles included managing the M&A activities for the sale of Bioproducts Laboratories Ltd and the financial and strategic work streams for the corporatisation of PBL out of the DH.